Brodalumab achieved primary endpoints for moderate to severe psoriasis at 52 weeksMarch 21, 2015Psoriatic Arthritis
Halting biologics before surgery tied to flares in psoriasis, psoriatic arthritisMarch 13, 2015Psoriatic Arthritis
Interleukin-23 inhibition with tildrakizumab achieves significant psoriasis improvementsMarch 9, 2015Psoriatic Arthritis
Ixekizumab improves lesions in patients with chronic plaque psoriasis after 20 weeksFebruary 24, 2015Psoriatic Arthritis
Joint mechanical stress: A psoriatic arthritis trigger in genetically susceptible individuals?January 29, 2015Psoriatic Arthritis
